CAR-T cell therapy for advanced plasma cell cancers
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This early-stage trial is testing a new type of cell therapy (CAR-T) that targets a protein called GPRC5D on your cancer cells. It aims to offer a treatment option when other therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer (like multiple myeloma) that has come back or not responded to treatment.
- Your cancer cells must have a specific marker called GPRC5D, which will be checked with a test.
- You must have already tried a stem cell transplant (from yourself or a donor) and it did not work.
- You need to be between 14 and 75 years old.
- You should be in fairly good overall health (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new type of cell therapy that uses your own immune cells (called CAR-T cells) to fight your cancer. The cells are modified to attack two specific targets on your cancer cells (BCMA and GPRC5D) to potentially improve treatment response.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
This trial tests a combination of drugs (bortezomib, lenalidomide, and dexamethasone) followed by a special cell therapy called CAR-T that targets a protein (BCMA) on cancer cells. It is for people with a rare and aggressive blood cancer called primary plasma cell leukemia who are not able to have a stem cell transplant.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Plasma Cell Dyscrasias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.